Suchergebnisse - "F0P408N6V4"

PubPharm (3.679)

41

enthalten in: Dermatologie (Heidelberg, Germany) | 2024

von Sunderkötter, C. | Bruns, T. | Pfeiffer, C.

42

Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma

enthalten in: Blood | 2024

von D'Agostino, M. | Bertuglia, G. | Rota-Scalabrini, D. | +22

CommentIn: Blood. 2024 Feb 15;143(7):564-566. - PMID 38358852

43

Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma : a cohort of a multicentre, single-arm, phase 1b/2 study

enthalten in: The Lancet. Haematology | 2024

von Abrisqueta, P. | González-Barca, E. | Panizo, C. | +13

44

Belantamab mafodotin, lenalidomide, and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma : Analysis of belantamab mafodotin-associated ocular adverse events and their impact on daily functioning from the part 1 of a phase 1/2 study

enthalten in: American journal of hematology | 2024

von Gavriatopoulou, M. | Ntanasis-Stathopoulos, I. | Malandrakis, P. | +11

45

Modeling and characterization of lenalidomide-loaded tripolyphosphate-crosslinked chitosan nanoparticles for anticancer drug delivery

enthalten in: International journal of biological macromolecules | 2024

von Jafari, A. | Morsali, A. | Bozorgmehr, M. | +2

46

Use Via Early Access to Ixazomib (UVEA-IXA) Study : Effectiveness and Safety of Ixazomib-based Therapy in Relapsed/Refractory Multiple Myeloma Outside of the Clinical Trial Setting

enthalten in: Clinical lymphoma, myeloma & leukemia | 2024

von Ludwig, H. | Ramasamy, K. | Mateos, M. | +10

47

Characteristics and Outcomes of Patients With Multiple Myeloma Who Developed Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome After Autologous Cell Transplantation

enthalten in: Transplantation and cellular therapy | 2024

von Yalniz, F. | Greenbaum, U. | Pasvolsky, O. | +17

48

Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma : final 5-year efficacy and safety findings in the phase II L-MIND study

enthalten in: Haematologica | 2024

von Duell, J. | Abrisqueta, P. | Andre, M. | +14

49

Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy : Final results of the phase 2 study DARIA

enthalten in: American journal of hematology | 2024

von Terpos, E. | Ntanasis-Stathopoulos, I. | Gavriatopoulou, M. | +11

50

Treatment Outcomes with Standard of Care in Relapsed/Refractory Diffuse Large B-Cell Lymphoma : Real-World Data Analysis

enthalten in: Advances in therapy | 2024

von Ip, A. | Mutebi, A. | Wang, T. | +7